Autor segons l'article: Rodríguez-Calvo, R; Girona, J; Alegret, JM; Bosquet, A; Ibarretxe, D; Masana, L
Departament: Medicina i Cirurgia
Autor/s de la URV: Alegret Colomé, Josep Maria / BOSQUET AGUDO, ALBA / Girona Tell, Josefa / Ibarretxe Gerediaga, Daiana / Masana Marín, Luis
Paraules clau: Heart failure Fabp4 Cardiovascular disease Adipokines fabp4 cardiovascular disease adipokines
Resum: Obesity and ectopic fat accumulation in non-adipose tissues are major contributors to heart failure (HF) and cardiovascular disease (CVD). Adipocytes act as endocrine organs by releasing a large number of bioactive molecules into the bloodstream, which participate in a communication network between white adipose tissue and other organs, including the heart. Among these molecules, fatty acid binding protein 4 (FABP4) has been recently shown to increase cardiometabolic risk. Both clinical and experimental evidence have identified FABP4 as a relevant player in atherosclerosis and coronary artery disease, and it has been directly related to cardiac alterations such as left ventricular hypertrophy (LVH) or both systolic and diastolic cardiac dysfunction. The available interventional studies preclude the establishment of a direct causal role of this molecule in CVD and HF and propose FABP4 as a biomarker rather than as an aetiological factor. However, several experimental reports have suggested that FABP4 may act as a direct contributor in cardiac metabolism and physiopathology, and pharmacological targeting of FABP4 may restore some of the metabolic alterations that are conducive to CVD and HF. Here, we review the current knowledge of FABP4 with regard to HF and CVD as well as the molecular basis of how this protein participates in the regulation of cardiac function.
Àrees temàtiques: Zootecnia / recursos pesqueiros Química Odontología Nutrição Medicina veterinaria Medicina iii Medicina ii Medicina i Materiais Interdisciplinar General medicine Farmacia Engenharias iv Engenharias iii Enfermagem Endocrinology, diabetes and metabolism Endocrinology & metabolism Endocrinology Educação física Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Ciência de alimentos Biotecnología Biodiversidade
Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/
ISSN: 00220795
Adreça de correu electrònic de l'autor: daiana.ibarretxe@urv.cat josefa.girona@urv.cat josefa.girona@urv.cat josepmaria.alegret@urv.cat luis.masana@urv.cat
Identificador de l'autor: 0000-0002-6267-8779 0000-0002-6267-8779 0000-0002-6117-5512 0000-0002-0789-4954
Data d'alta del registre: 2024-09-07
Versió de l'article dipositat: info:eu-repo/semantics/acceptedVersion
Enllaç font original: https://joe.bioscientifica.com/view/journals/joe/233/3/R173.xml
URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/
Referència a l'article segons font original: Journal Of Endocrinology. 233 (3): R173-R184
Referència de l'ítem segons les normes APA: Rodríguez-Calvo, R; Girona, J; Alegret, JM; Bosquet, A; Ibarretxe, D; Masana, L (2017). Role of the fatty acid-binding protein 4 in heart failure and cardiovascular disease. Journal Of Endocrinology, 233(3), R173-R184. DOI: 10.1530/JOE-17-0031
DOI de l'article: 10.1530/JOE-17-0031
Entitat: Universitat Rovira i Virgili
Any de publicació de la revista: 2017
Tipus de publicació: Journal Publications